- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06309745
THERApy De-escalation for TESTicular Cancer (THERATEST)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
THERATEST is an observational cohort study of patients receiving SOC treatments (combination chemotherapy or radiotherapy) or de-escalated treatments (primary rRPLND or Carboplatin AUC10) treatments for stage II seminoma.
Potential patients will be identified and invited to join the THERATEST study. Patients will be allocated to the following cohorts based on whether the relevant mode of treatment is adopted as an institutional SOC in their respective institution:
A. rRPLND cohort: Patients with seminoma who are negative/low for tumour markers and unifocal ipsilateral Stage IIA or <3cm IIB will be assessed for rRPLND. Patients who are eligible for rRPLND will undergo surgery followed by adjuvant treatment or surveillance as determined by their clinical teams based on post-operative histology as per SOC. Patients who are not deemed eligible for or decline rRPLND, will be offered either BEP/EP chemotherapy or radiotherapy with or without neoadjuvant Carboplatin AUC7 and will continue to be followed in the study.
B. Carboplatin AUC10 cohort: Patients with stage II seminoma will be offered Carboplatin AUC10. Those deemed ineligible for Carboplatin AUC10 or who decline this treatment option will be offered either BEP/EP chemotherapy or radiotherapy and will continue to be followed in the study.
Chemotherapy treatment strategies and adjuvant treatments are left to the shared decision-making between treating clinician and patient and follow institutional SOC. In both cohorts patients will be followed up for 2 years after treatment completion or until death or withdrawal of consent, whichever is the earliest. Beyond the study period, patients will be follow up as per institutional SOC protocols as part of prospective institutional audits.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Theratest study coordinator
- Phone Number: 020 7882 8478
- Email: bci-theratest@qmul.ac.uk
Study Locations
-
-
-
London, United Kingdom
- Recruiting
- Barts and London Hospital NHS Trust
-
Contact:
- THERATEST Study coordinator
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
A. rRPLND cohort: Patients with seminoma who are negative/low for tumour markers and unifocal ipsilateral Stage IIA or <3cm IIB will be assessed for rRPLND. Patients who are eligible for rRPLND will undergo surgery followed by adjuvant treatment or surveillance as determined by their clinical teams based on post-operative histology as per SOC. Patients who are not deemed eligible for or decline rRPLND, will be offered either BEP/EP chemotherapy or radiotherapy with or without neoadjuvant Carboplatin AUC7 and will continue to be followed in the study.
B. Carboplatin AUC10 cohort: Patients with stage II seminoma will be offered Carboplatin AUC10. Those deemed ineligible for Carboplatin AUC10 or who decline this treatment option will be offered either BEP/EP chemotherapy or radiotherapy and will continue to be followed in the study.
Description
Inclusion Criteria:
Each patient must meet all of the following inclusion criteria to be enrolled in the study:
- Willing and able to provide written informed consent.
- Male.
- Age ≥ 16 years.
- Histologically confirmed seminoma (biopsy/orchidectomy)
- Clinical stage II (standard of care cross-sectional imaging).
- Ability to comply with the protocol, including but not limited to, completion of the patient-reported outcome questionnaires.
rRPLND cohort specific inclusion criteria
Participants must meet the following additional inclusion criteria to register for the rRPLND cohort:
- Stage IIA and <3cm IIB with unifocal ipsilateral lymph node within rRPLND template.
Negative or mildly elevated serum tumour markers, defined as:
- AFP (alpha-fetoprotein) <10ng/ml and non-rising on serial testing
- BhCG (human chorionic gonadotropin) <50mg/ml
- LDH (lactate dehydrogenase) <1.5x upper limit normal
Fit for surgery, defined as meeting all of the following criteria:
- Body mass index (BMI) <34
- Charlson comorbidity index ≤3
- ECOG Performance status 0-1
- No significant cardio-pulmonary disease, or other uncontrolled intercurrent illness that would limit fitness for surgery in the opinion of the investigator
- No previous open intra-abdominal surgery
Carboplatin AUC10 cohort specific inclusion criteria
Participants must meet the following additional inclusion criteria to register for the Carboplatin AUC10 group:
Serum tumour markers, defined by IGCCCG "good risk" criteria:
- AFP <10ng/ml
- any BhCG
- LDH <2.5x ULN
- Glomerular filtration rate by EDTA clearance over 25 ml/min (a measured creatinine clearance using Cockcroft and Gault would be allowed if unable to perform EDTA clearance).
- ECOG Performance status 0-2.
- Patients must be sterile or agree to use adequate contraception during the period of therapy.
Exclusion Criteria:
- Raised AFP > 10ng/ml that does not fall to <10ng/ml following orchidectomy
- Previous chemotherapy or radiotherapy for the disease under study.
- Previous or concurrent malignancy other than testicular cancer, unless treated with curative intent and with no known active disease present for ≥2 years before enrolment and felt to be at low risk for recurrence by the treating physician (for example: non-melanoma skin cancer or lentigo maligna; breast ductal carcinoma in situ; prostatic intraepithelial neoplasia; urothelial papillary non-invasive carcinoma or urothelial carcinoma in situ).
- Any condition that, in the opinion of the investigator, would interfere with evaluation of study intervention or interpretation of patient safety or study results such as medical comorbidities impacting on QoL or medical conditions or other disorders that would affect adherence to study requirements
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
RPLND cohort
Patients with seminoma who are negative/low for tumour markers and unifocal ipsilateral Stage IIA or <3cm IIB will be assessed for rRPLND.
Patients who are eligible for rRPLND will undergo surgery followed by adjuvant treatment or surveillance as determined by their clinical teams based on post-operative histology as per SOC.
Patients who are not deemed eligible for or decline rRPLND, will be offered either BEP/EP chemotherapy or radiotherapy with or without neoadjuvant Carboplatin AUC7 and will continue to be followed in the study.
|
retroperitoneal lymph node dissection
|
Carboplatin AUC10 cohort
Patients with stage II seminoma will be offered Carboplatin AUC10.
Those deemed ineligible for Carboplatin AUC10 or who decline this treatment option will be offered either BEP/EP chemotherapy or radiotherapy and will continue to be followed in the study.
|
Carboplatin AUC10
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
FEASIBILITY of recruitment and retention
Time Frame: through study completion, an average of 3 year
|
To demonstrate feasibility of recruitment and retention (number of participants recruited per month and retained annually).
Completion of recruitment of 30 patients into the THERATEST study, and measurement of overall patient retention within the trial until the 2-year follow-up visit.
|
through study completion, an average of 3 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
QUALITY OF LIFE assessed by difference in HRQOL scores
Time Frame: through study completion, an average of 3 year
|
To determine differences in Health-related QOL (HRQOL) before and after treatment(s).
Change in domain scale scores/single item scores in European Organisation for Research and Treatment of Cancer (EORTC) QLQ-TC26 and EORTC QLQ-C30, measured from baseline until the 2-year follow-up visit.
|
through study completion, an average of 3 year
|
QUALITY OF LIFE assessed by difference in differences in sexual drive, function, and overall satisfaction
Time Frame: through study completion, an average of 3 year
|
To determine differences in sexual drive, function, and overall satisfaction before and after treatment(s).
Change in domain scale scores/single item scores in Brief Male Sexual Function Inventory (BMSFI), QLQ-TC26, and supplementary questions on retrograde ejaculation.
Measured from baseline until the 2-year follow-up visit.
|
through study completion, an average of 3 year
|
Progression free SURVIVAL
Time Frame: through study completion, an average of 3 year
|
• To determine progression-free survival (PFS) and overall survival (OS) rates ensuring these fall in line with standard of care treatments outcomes (>95%).
PFS rate at 2 years, defined as the proportion of patients who did not experience disease progression or death from any cause during the 2-year follow-up period.
|
through study completion, an average of 3 year
|
OVERALL SURVIVAL
Time Frame: through study completion, an average of 3 year
|
• To determine progression-free survival (PFS) and overall survival (OS) rates ensuring these fall in line with standard of care treatments outcomes (>95%).
OS rate at 2 years, defined as the proportion of patients who did not experience death from any cause during the 2-year follow-up period.
|
through study completion, an average of 3 year
|
SAFETY and complication of all treatments
Time Frame: through study completion, an average of 3 year
|
• To assess the safety and complications of all treatments. Incidence, nature and severity of adverse events with severity determined according to CTCAE v5.0 collected from consent until 6 weeks post-surgery or chemotherapy. Surgical complications will be assessed by the Clavien-Dindo scoring system, and analysing details of surgical complications, blood transfusion, ITU admission and dialysis rates from patient records up to 6 months post-rRPLND. |
through study completion, an average of 3 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Prabhakar Rajan, Queen Mary University of London
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Endocrine System Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Genital Neoplasms, Male
- Testicular Diseases
- Neoplasms, Germ Cell and Embryonal
- Germinoma
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases, Male
- Genital Diseases
- Testicular Neoplasms
- Seminoma
- Antineoplastic Agents
- Carboplatin
Other Study ID Numbers
- THERATEST
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Seminoma
-
University of Southern CaliforniaNational Cancer Institute (NCI)Active, not recruitingLymphadenopathy | Stage I Testicular Seminoma | Stage II Testicular SeminomaUnited States
-
University Health Network, TorontoRecruitingStage II Testicular Seminoma | Lymphadenopathy RetroperitonealCanada
-
Barts & The London NHS TrustUniversity College London HospitalsCompletedMetastatic SeminomaUnited Kingdom
-
Abramson Cancer Center of the University of PennsylvaniaMassachusetts General HospitalCompleted
-
Tata Memorial CentreNot yet recruiting
-
Gustave Roussy, Cancer Campus, Grand ParisRecruiting
-
Swiss Group for Clinical Cancer ResearchActive, not recruiting
-
Heinrich-Heine University, DuesseldorfRecruiting
-
Centre Leon BerardRecruiting
-
Daiichi Sankyo, Inc.TerminatedNon-CNS Germ Cell Tumors (Seminomas and Nonseminomas)United States, France, United Kingdom
Clinical Trials on retroperitoneal lymph node dissection
-
University Health Network, TorontoRecruitingStage II Testicular Seminoma | Lymphadenopathy RetroperitonealCanada
-
Heinrich-Heine University, DuesseldorfUnknownStage II A/B Seminomatous Germ Cell TumorsGermany
-
University of Southern CaliforniaNational Cancer Institute (NCI)Active, not recruitingLymphadenopathy | Stage I Testicular Seminoma | Stage II Testicular SeminomaUnited States
-
RenJi HospitalUnknown
-
Shanghai Zhongshan HospitalNot yet recruiting
-
Eastern Hepatobiliary Surgery HospitalUnknownIntrahepatic CholangiocarcinomaChina
-
Fujian Medical UniversityUnknown
-
Saint John's Cancer InstituteNational Institutes of Health (NIH)Completed
-
Tianjin Medical University Cancer Institute and...RecruitingLung Neoplasms | Lymph Node ExcisionChina
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...CompletedBreast Neoplasm Female